Exosomes and Their Regulatory Implications in Dermatology

The presentation primarily critiques the use and regulation of exosomes in dermatology, highlighting their unproven efficacy and lack of FDA approval for injection. It emphasizes that most current studies involve animal models and do not provide sufficient evidence for their use in human applications. The speaker discusses the importance of understanding the potential risks associated with exosome treatments, including legal implications and the possibility of containing prohibited substances, particularly for athletes. Additionally, they criticize the disparity in regulatory scrutiny between established medical products and those derived from exosomes, suggesting that practitioners could be misled by companies promoting such treatments without robust clinical evidence. The speaker encourages clinicians to be cautious, seek tangible evidence for new treatments, and ensure they remain informed about the products they use. While acknowledging the promising preliminary data from rodent studies, the speaker calls for continued research and adherence to high medical standards before endorsing exosome therapies in dermatology.